	US 11,672,850 B2
	Compositions and method for optimized peptide vaccines using residue optimization
David Kenneth Gifford, Newton, MA (US); and Brandon Carter, Cambridge, MA (US)
Assigned to Think Therapeutics, Inc., Newton, MA (US)
Filed by Think Therapeutics, Inc., Newton, MA (US)
Filed on Apr. 26, 2022, as Appl. No. 17/729,290.
Application 17/729,290 is a continuation of application No. 17/243,096, filed on Apr. 28, 2021.
Prior Publication US 2022/0370584 A1, Nov. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 38/00 (2006.01); A61K 38/10 (2006.01); A61K 38/08 (2019.01); A61K 38/04 (2006.01); C07K 5/00 (2006.01); C07K 7/00 (2006.01); C07K 16/00 (2006.01); C07K 17/00 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); A61P 35/00 (2006.01); A61K 48/00 (2006.01)

CPC A61K 39/00116 (2018.08) [A61K 38/08 (2013.01); A61K 38/10 (2013.01); A61K 39/001152 (2018.08); A61K 39/001158 (2018.08); A61P 35/00 (2018.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); A61K 48/00 (2013.01); A61K 2039/812 (2018.08); A61K 2039/82 (2018.08); A61K 2039/86 (2018.08)]

30 Claims

1. An immunogenic composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 7882, SEQ ID NO: 7884, SEQ ID NO: 7887, SEQ ID NO: 7888, SEQ ID NO: 7894, SEQ ID NO: 7898, SEQ ID NO: 7899, SEQ ID NO: 7900, SEQ ID NO: 7901, SEQ ID NO: 7904, SEQ ID NO: 7905, SEQ ID NO: 7906, SEQ ID NO: 7920, SEQ ID NO: 7921, SEQ ID NO: 7926, SEQ ID NO: 7932, SEQ ID NO: 7933, SEQ ID NO: 7934, SEQ ID NO: 7936, SEQ ID NO: 7937, SEQ ID NO: 7940, SEQ ID NO: 7950, SEQ ID NO: 7951, SEQ ID NO: 7953, SEQ ID NO: 7954, SEQ ID NO: 7970, SEQ ID NO: 7972, SEQ ID NO: 7976, SEQ ID NO: 7982, SEQ ID NO: 8139, SEQ ID NO: 8267, SEQ ID NO: 8269, SEQ ID NO: 8272, SEQ ID NO: 8277, SEQ ID NO: 8296, and SEQ ID NO: 8422.